Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01871545 · ClinicalTrials.gov registry record · NA

Evaluation of Liver Cancer With Magnetic Resonance Imaging (MRI)

A NA study of Hepatocellular Carcinoma and HCC, sponsored by Icahn School of Medicine at Mount Sinai.

Completed
Registry status
NA
Development phase
84
Enrollment target
1
Study location

NCT01871545 is a NA study of Hepatocellular Carcinoma and HCC that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 84 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01871545, a NA study of Hepatocellular Carcinoma and HCC, has completed, sponsored by Icahn School of Medicine at Mount Sinai.

COMPLETED
Registry status
NA
Development phase
84 participants
Enrollment target
1
Study location

Study Summary

The incidence of hepatocellular carcinoma (HCC) has recently increased in the United States. Although imaging plays a major role in HCC screening and staging, the possibility of predicting HCC tumor grade, aggressiveness, angiogenesis and hypoxia with imaging are unmet needs. In addition, new antiangiogenic drugs now available to treat advanced HCC necessitate the use of new imaging criteria beyond size. The investigators would like to develop and validate non-invasive magnetic resonance imaging (MRI) methods based on advanced diffusion-weighted imaging (DWI), MR Elastography, BOLD (blood oxygen level dependent) MRI and perfusion-weighted imaging (PWI, using gadolinium contrast) to be used as non-invasive markers of major histopathologic features of HCC, and to predict and assess early response of HCC to systemic therapy. The investigators also would like to develop quality control tools to improve the quality and decrease variability of quantitative MRI metrics. These techniques combined could represent non-invasive correlates of histologic findings in HCC, could enable individualized therapy, and provide prognosis in patients with HCC.

Interventions

  • DEVICE Magnetic Resonance Imaging

Study Locations (1)

New York

  • Icahn School of Medicine at Mount Sinai - New York

Trial Details

FieldValue
Enrollment Target 84 participants
Start Date 2013-06
Est. Completion 2018-02-02
Phase NA

What the Registry Record Tells You About NCT01871545

The ClinicalTrials.gov registry entry for NCT01871545 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (67% lower). The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Magnetic Resonance Imaging is the first listed.

NCT01871545 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT01871545 about?

NCT01871545 is a clinical study titled "Evaluation of Liver Cancer With Magnetic Resonance Imaging (MRI)". The incidence of hepatocellular carcinoma (HCC) has recently increased in the United States. Although imaging plays a major role in HCC screening and staging, the possibility of predicting HCC tumor grade, aggressiveness, angiogenesis and hypoxia with imaging are unmet needs. In addition, new antian...

What is the current status of trial NCT01871545?

This trial is currently completed. It is a NA study. The enrollment target is 84 participants. The study started on 2013-06. Estimated completion is 2018-02-02.

What conditions does trial NCT01871545 study?

This clinical trial studies the following conditions: Hepatocellular Carcinoma, HCC.

What interventions are being tested in trial NCT01871545?

The interventions under investigation include: Magnetic Resonance Imaging (DEVICE).

Who is sponsoring clinical trial NCT01871545?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01871545 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hepatocellular Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.